Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunitybio Inc IBRX

Healthcare Biotechnology
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as... see more

Recent & Breaking News (NDAQ:IBRX)

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer 

Business Wire September 9, 2024

ImmunityBio's ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

Business Wire August 12, 2024

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

Business Wire August 6, 2024

IMMUNITYBIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX

Business Wire July 26, 2024

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm

PR Newswire July 25, 2024

Notice to Long-Term Shareholders of ImmunityBio, Inc. (IBRX): Grabar Law Office Is Investigating Claims on Your Behalf

Newsfile July 1, 2024

Grabar Law Office Investigates Claims on Behalf of Shareholders of ImmunityBio, Inc. (IBRX)

Newsfile June 27, 2024

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval-Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

Business Wire June 20, 2024

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

Business Wire June 7, 2024

Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

Business Wire May 17, 2024

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm

Newsfile May 16, 2024

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

Business Wire May 7, 2024

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

Business Wire May 2, 2024

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association

Business Wire April 30, 2024

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

Business Wire April 25, 2024

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Business Wire April 22, 2024

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm

Newsfile March 15, 2024

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

Business Wire March 6, 2024

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

Business Wire March 5, 2024

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Business Wire February 21, 2024